These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 7453714)

  • 21. MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis.
    Yeh JH; Chen WH; Chiu HC; Bai CH
    J Neurol Sci; 2007 Dec; 263(1-2):191-3. PubMed ID: 17602704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of myasthenia gravis with dropped head: a report of 2 cases and review of the literature.
    Tamai M; Hashimoto T; Isobe T; Sato H; Doden T; Nakano T
    Neuromuscul Disord; 2015 May; 25(5):429-31. PubMed ID: 25747003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surgical outcome in thymic tumors with myasthenia gravis after plasmapheresis--a comparative study.
    Sarkar BK; Sengupta P; Sarkar UN
    Interact Cardiovasc Thorac Surg; 2008 Dec; 7(6):1007-10. PubMed ID: 18682429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Plasma exchange in myasthenia gravis].
    Redeker M; Meyer-Wahl L
    Nervenarzt; 1982 Dec; 53(12):729-32. PubMed ID: 7155236
    [No Abstract]   [Full Text] [Related]  

  • 25. Current trends in the management of myasthenia gravis: plasmapheresis and immunosuppressive therapy.
    Pollard JD; Basten A; Hassall JE; Kronenberg H; Cobcroft R; Dawkins R
    Aust N Z J Med; 1980 Apr; 10(2):212-7. PubMed ID: 6930213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients.
    Dau PC
    Ann N Y Acad Sci; 1981; 377():700-8. PubMed ID: 6951494
    [No Abstract]   [Full Text] [Related]  

  • 27. [Myasthenia gravis; clinical aspects, pathophysiology and treatment].
    Oosterhuis HJ
    Ned Tijdschr Geneeskd; 1983 Sep; 127(39):1765-71. PubMed ID: 6314161
    [No Abstract]   [Full Text] [Related]  

  • 28. Plasmapheresis does not affect polysomnographic parameters in patients with myasthenia gravis: a case series study.
    Yeh JH; Chen WH; Chiu HC; Lee CT; Hsu CY
    Artif Organs; 2010 Jun; 34(6):E200-3. PubMed ID: 20456321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasmapheresis: a new treatment modality for the patient with severe myasthenia gravis.
    Eppel M; Streib EW
    Nebr Med J; 1982 Apr; 67(4):72-4. PubMed ID: 7088214
    [No Abstract]   [Full Text] [Related]  

  • 30. [Plasma exchange combined with immunosuppressive therapy in myasthenia gravis].
    Tanaka M; Nagai H; Mori S; Miyatake T; Shinada S
    No To Shinkei; 1982 Jul; 34(7):699-703. PubMed ID: 7138697
    [No Abstract]   [Full Text] [Related]  

  • 31. [Plasmapheresis in patients with myasthenia gravis].
    Konishi T
    Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical spectrum of myasthenia gravis and problems of management.
    Dhamija RM; Venkataraman S; Roy AK; Sanchetee PC; Bhargava AK
    J Assoc Physicians India; 1991 Feb; 39(2):181. PubMed ID: 1885481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of plasmapheresis in myasthenia gravis.
    Perlo VP; Shahani BT; Huggins CE; Hunt J; Kosinski K; Potts F
    Ann N Y Acad Sci; 1981; 377():709-24. PubMed ID: 6951495
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasmapheresis as a guide for azathioprine therapy in prednisone-resistant myasthenia gravis.
    Rodnitzky RL; Bosch EP
    Muscle Nerve; 1981; 4(6):529-30. PubMed ID: 7311992
    [No Abstract]   [Full Text] [Related]  

  • 35. [Assay of acetylcholine receptor antibodies in myasthenia gravis. A study of 329 sera (author's transl)].
    Morel E; Raimond F; Goulon-Goëau C; Berrih S; Vernet-Der-Garabedian B; Harb J; Bach JF
    Nouv Presse Med; 1982 May; 11(24):1849-54. PubMed ID: 7110933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postthymectomy myasthenia gravis: relationship with thymoma and antiacetylcholine receptor antibody.
    Nakajima J; Murakawa T; Fukami T; Sano A; Takamoto S; Ohtsu H
    Ann Thorac Surg; 2008 Sep; 86(3):941-5. PubMed ID: 18721587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis.
    Pompeo E; Tacconi F; Massa R; Mineo D; Nahmias S; Mineo TC
    Eur J Cardiothorac Surg; 2009 Jul; 36(1):164-9. PubMed ID: 19339195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Plasmapheresis in combined treatment of severe generalized myasthenia].
    Vetshev PS; Shkrob OS; Sanadze AG; Khodzhaev ZSh; Ippolitov IKh; Chilingaridi KE; Vanushko VE
    Khirurgiia (Mosk); 1991 Apr; (4):95-102. PubMed ID: 2062079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis.
    Takahashi H; Kawaguchi N; Nemoto Y; Hattori T
    J Neurol Sci; 2006 Sep; 247(2):239-41. PubMed ID: 16876198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term treatment of myasthenia gravis with immunoadsorption.
    Haas M; Mayr N; Zeitlhofer J; Goldammer A; Derfler K
    J Clin Apher; 2002; 17(2):84-7. PubMed ID: 12210711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.